Celltrion receives EC Approval for Avtozma® (CT-P47), a biosimilar to RoActemra® (tocilizumab)
- Avtozma® (CT-P47), a biosimilar referencing RoActemra® (tocilizumab) is approved by the European Commission (EC) for all indications of the reference product[i]
- EC approval is based on a comprehensive data package demonstrating Avtozma®’s biosimilarity to RoActemra®[ii],iii
- Celltrion’s biosimilar portfolio continues to grow, expanding treatment options to meet the needs of people with immune diseases
INCHEON, SOUTH KOREA – Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a biosimilar referencing RoActemra® (tocilizumab). Avtozma® has been approved for all indications of its reference product, including moderate to severely active rheumatoid arthritis (RA), active systemic juvenile idiopathic arthritis (sJIA), polyarticular juvenile idiopathic arthritis (pJIA) and giant cell arteritis (GCA).i The approval further strengthens Celltrion’s growing immunology portfolio.
“Today’s approval of Avtozma®, a biosimilar to RoActemra®, marks a critical step in Celltrion’s mission to provide European healthcare systems with affordable, effective solutions for immunological disorders. By leveraging our integrated operations, we strengthen the stability of supply chains and enhance collaboration with European healthcare professionals,” said Taehun Ha, Vice President and Head of Europe at Celltrion. “We are committed to delivering value-driven solutions tailored to the unique needs of the European market.”
The EC approval on Avtozma® was supported by a comprehensive data package and totality of evidence, including the results from a phase III study demonstrating biosimilarity between Avtozma® and the reference product. The primary endpoint was met in terms of mean change from baseline in Disease Activity Score (DAS) using 28 joints (DAS28)-ESR at Week 12, and the final results supported comparability in secondary efficacy, pharmacokinetics (PK), safety and immunogenicity results between Avtozma® and RoActemra®.ii,[iii]
Avtozma® is Celltrion’s twelfth biosimilar product approved by the EC, following the approval of Remsima® (intravenous infliximab), Remsima® SC (subcutaneous infliximab), Yuflyma® (adalimumab), SteQeyma® (ustekinumab), Truxima® (rituximab), Herzuma® (trastuzumab), Vegzelma® (bevacizumab), Omlyclo® (omalizumab), Eydenzelt® (aflibercept), Stoboclo® and Osenvelt® (denosumab).
[i] European Medicines Agency Summary of Product Characteristics (SmPC), Avtozma®. [Last accessed February 2025].
[ii] Smolen JS et al., Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47. RMD Open. 2024;10(4), e004514. Available at: https://rmdopen.bmj.com/content/10/4/e004514.abstract [Last accessed February 2025]
[iii] Gerd Burmester et al., Similar Efficacy, PK, Safety, and Immunogenicity of Tocilizumab Biosimilar (CT-P47) and Reference Tocilizumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Week 52 Results from the Phase III Single Transition Study. Poster Presentation (abstract no. 0502). Presented at ACR 2024. Available at: https://acrabstracts.org/abstract/similar-efficacy-pk-safety-and-immunogenicity-of-tocilizumab-biosimilar-ct-p47-and-reference-tocilizumab-in-patients-with-moderate-to-severe-active-rheumatoid-arthritis-week-52-results-from-the/ [Last accessed February 2025]
